SAB Biotherapeutics (SABS)
NASDAQ:SABS
SABS Stock Chart & Stats
$3.87
$0.50(13.16%)
At close: 4:00 PM EST
$3.87
$0.50(13.16%)
Day’s Range― - ―
52-Week Range$1.00 - $6.60
Previous CloseN/A
Volume58.44K
Average Volume (3M)398.22K
Market Cap
$200.24M
Enterprise Value$32.44M
Total Cash (Recent Filing)$96.59M
Total Debt (Recent Filing)$5.95M
Price to Earnings (P/E)―
Beta0.86
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding50,951,040
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.37
Enterprise Value/Ebitda1.95
Forecast
1Y Price Target
$10.50Price Target Upside171.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biological Proof Of ConceptPhase 1 findings showed preservation and an increase in C-peptide in treated patients versus placebo, indicating a biological signal for beta cell preservation.
Regulatory And Trial AdvancementAgreement with the U.S. regulator on trial design, expansion of the registrational trial to many global sites, and a well-subscribed private financing together provide a clear pathway and capital to advance pivotal testing.
Safety And Re-dosing FeasibilitySafety data reported no serum sickness, no anti-drug antibody related adverse events, and only mild transient side effects, supporting tolerability and the feasibility of repeated dosing.
Bears Say
Data Robustness And Sample SizeA very small treatment cohort and baseline differences versus placebo limit confidence in early efficacy signals and increase the likelihood that larger, more balanced trials will be required to confirm benefit.
Efficacy Risk In Adult PatientsReduced beta cell resilience and greater metabolic stress in adult patients make C-peptide preservation more challenging, raising the risk that efficacy may be attenuated in older populations.
SAB Biotherapeutics News
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $1.00 and its highest was $6.60 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
SAB Biotherapeutics’s market cap is $200.24M.
When is SAB Biotherapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SAB Biotherapeutics’s earnings last quarter?
Currently, no data Available
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 50,951,040 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Currently, no hedge funds are holding shares in SABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SAB Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (171.32% Upside)
$10.50 (171.32% Upside)
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.05%
12-Months-Change
Fundamentals
Return on Equity
-21.16%
Trailing 12-Months
Asset Growth
-51.32%
Trailing 12-Months
Company Description
SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
SABS Stock 12 Month Forecast
Average Price Target
$10.50
▲(171.32% Upside)